先天性胆总管囊肿23例的术式及疗效分析

目的：探讨先天性胆总管囊肿的术式及疗效。方法：回顾分析手术治疗先天性胆总管囊肿23例，其中Roux-Y囊肿-空肠吻合8例；囊肿切除，Roux-Y肝总管-空肠吻合15例。结果：20例获得随访，Roux-Y囊肿-空肠吻合随访6例，仅2例无症状，另4例反复发作腹痛，发热或黄疸，其中1例再手术，囊肿切除，Roux-Y肝总管-空肠吻合随访14例。仅1例有腹痛，余13例无症状，结论：Roux-Y肝总管-空肠吻合是治疗先天性胆总管囊肿的首选术式。     

痛结宁胶囊治疗乳腺增生病的临床疗效观察

目的 :评价痛结宁胶囊治疗乳腺增生病的临床疗效。方法 :30 0例乳腺增生病病人随机分成两组。治疗组 2 4 0例 ,口服痛结宁胶囊 ,每次 3粒 ,1日 3次。对照组 60例 ,口服维生素 E,1 0 0 mg,1日 1次。疗程 3个月。用 Ridit检验分析疗效。结果 :治疗组治愈率 2 1 .67% ,总有效率 88.75 % ;对照组治愈率 1 1 .67% ,总有效率 46.67% ,治疗组疗效明显优于对照组 ( P<0 .0 1 )。结论 :痛结宁治疗乳腺增生病有较好的疗效 ,病程越短 ,疗效越好 ,延长治疗时间可以提高治疗效果     

仙草消毒液杀灭微生物效果与毒性的试验观察

仙草消毒液为含 3 0 %乙醇的植物消毒剂 ,其中包括五味子、细辛、丁香等成分 ,p H6.0 1。为了解其杀灭微生物效果及其毒性 ,进行了载体定量杀菌试验及毒性试验。结果 ,1∶ 1的水稀释液对金黄色葡萄球菌作用2分钟 ,1∶ 2的稀释液对金黄色葡萄球菌作用 8分钟 ,以其原液对白色念珠菌作用 2 min,平均杀灭率均大于99.90 %。小牛血清对其杀灭效果有影响 ,原液经 5 4℃存放 14天 ,杀菌效果无明显变化。以其原液对雌、雄小鼠经口 LD50 >5 0 0 0 mg/Kg,对大耳白兔一次眼、皮肤刺激试验平均积分指数为 0 ,微核试验阴性 ,蓄积毒性试验为弱蓄积毒性     

影响利培酮治疗精神分裂症疗效因素分析

目的　探讨影响利培酮对精神分裂症疗效的关键因素。方法　对 57例单用利培酮治疗的精神分裂症患者 ,采用一系列标准评定工具对 39个临床指标进行定量或半定量评估。并作Logistic回归分析。将治疗后简明精神病评定量表 (BPRS)减分率≥ 30 %者确定为“有效”。结果　单因素分析显示 :服药依从性 ,MMPI中Sc、Si、D因子 ,治疗前BPRS 2和BPRS 4因子 ,TESS 3因子 ,家族史 ,起病形式 ,意识模糊 ,住院时间与利培酮疗效有关 ;经多因素分析有服药依从性 ,MMPI(Sc) ,BPRS 2 ,家族史 ,意识模糊等 5个指标选入回归方程。结论　影响利培酮对精神分裂症疗效的关键因素依次为服药依从性 ,MMPI中精神分裂因子 ,阴性症状 ,家族史及意识模糊     

妊娠合并肝内胆汁郁积症的围生儿结局57例分析

目的 探讨妊娠合并肝内胆汁郁积症（ICP）患者致围生儿不良结局的相关指标。方法 总结本院57例ICP患者的相关临床资料，将其与围生儿结局进行分组对照分析。结果 血清胆汁酸升高与围生儿不良结局关系不明显（P＞0.05)；血清转氨酶水平在产生围生儿不良结局组与未产生围生儿不良结局组之间有显著性差异（P＞0.01)；皮肤瘙痒持续时间大于3周组围生儿不良结局发生率与持续时间小于3周组有显著性差异（P＜0.05)；有、无NST基线变异消失组的围生儿不良结局发生率有极显著性差异（P＜0.01)。结论 血清转氨酶水平、皮肤瘙痒持续时间及NST基线变异是否消失是预示围生儿不良结局的相关指标。     

Measuring the Quality of Hospital-based Domestic Violence Programs

OBJECTIVE: To obtain consensus among a panel of experts on performance measures useful for evaluating the quality of hospital-based domestic violence (DV) programs. METHODS: The Delphi process of consensus development was used with a panel of 18 experts including DV researchers, program planners, and advocates. Three rounds were conducted over a period of six months, with each round involving the completion of a written questionnaire. Panelists were instructed to concentrate on structure and process measures of DV program performance. Health outcome measures were not considered. During each round, panelists rated (scale of 1-5) their level of agreement with each measure, in terms of the measure's usefulness for evaluating hospital-based DV programs. Data were entered into SPSS on a personal computer and frequency distributions, measures of central tendency, and variance were computed for each measure. Consensus development was defined as a reduction in the item-specific variance from one round to the next. RESULTS: A total of 37 performance measures were agreed upon. These measures fell within nine different domains of DV program activities, including: Policies and Procedures, Hospital Physical Environment, Hospital Cultural Environment, Training of Providers, Screening and Safety Assessment, Documentation, Intervention Services, Evaluation Activities, and Collaboration. CONCLUSIONS: A number of measures have been identified as useful for evaluating hospital-based DV programs. Use of these measures should assist researchers, program planners, and administrators in assessing the quality of hospital-based DV programs.     

东莨菪碱诱发染色体畸变的剂量效应

东茛菪碱五个剂量(1、2、5、10、20μg/ml作用于12名健康成人外周血淋巴细胞培养液诱发染色体畸变,并设空白对照组(生理盐水)。染色体畸变率分别为3.±0.5,9.6±1.1,11.7±1.1,13.6±2.3,18.0±3.0和17.5±2.0％;细胞畸变率为3.1±0.6,9.2±0.6,10.0±0.8,10.8±1.5,11.6±1.8和12.2±14.％。各剂量组与对照组比较差异高度显著(P<0.01)。方差分析,各剂量组间变异的差异高度显著(P<0.01)。相关系数和回归系数也非常显著(P<0.01)。结果表明,东莨菪碱剂量与染色体畸变率和细胞畸变率有线性关系。     

Long‐term efficacy of biologics in the treatment of psoriasis: what do we really know?

Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab).     

Functioning and disability 6–15 years after traumatic brain injuries in northern Sweden

Objectives –  To assess long‐term functioning and disability after traumatic brain injury (TBI). Material and methods –  Individuals (n = 88) in Norrbotten, northern Sweden, who had been transferred for neurosurgical care were assessed with internationally established TBI outcome measures 6–15 years post‐injury. Results –  There was an improvement in overall outcome from discharge from inpatient rehabilitation to follow‐up. Many individuals had a high degree of motor and cognitive functioning, which enabled them to live independently in their own home without assistance, but there remained a disability related to community reintegration and social participation. This affected their productivity and to some degree their marital stability. The remaining disability and reduced productivity were related to the age at injury and the injury severity. Conclusions –  Our data showed that individuals with a TBI can achieve and maintain a high degree of functioning many years after the injury. Increasing age and a greater injury severity contributed to their long‐term disability.